Vice-President

Medicine & Life Sciences

1. Abatacept 15%
2. Adalimumab 17%
3. Adenocarcinoma 13%
4. Anti-Idiotypic Antibodies 10%
5. Antibodies 19%
6. Antigens 9%
7. Antirheumatic Agents 16%
8. Atopic Dermatitis 12%
9. Autoantibodies 29%
10. Autoimmune Diseases 12%
11. B-Lymphocytes 10%
12. baricitinib 17%
13. Biomarkers 13%
14. Blister 12%
15. Bone and Bones 12%
16. Breast Neoplasms 18%
17. Bullous Pemphigoid 14%
18. C-Reactive Protein 10%
19. Carcinoma 14%
20. Chemoradiotherapy 23%
21. Cisplatin 19%
22. Cohort Studies 12%
23. Colorectal Neoplasms 26%
24. Desmoglein 1 25%
25. Desmoglein 3 49%
26. Desmogleins 19%
27. Drug Therapy 26%
28. Esophageal Neoplasms 84%
29. Esophageal Squamous Cell Carcinoma 47%
30. Esophagectomy 64%
31. Esophagus 12%
32. filaggrin 11%
33. Fluorouracil 19%
34. Gastrectomy 18%
35. Gastrointestinal Neoplasms 14%
36. Genes 13%
37. Hepatocellular Carcinoma 11%
38. Immunoglobulin G 26%
39. Immunoglobulin G4-Related Disease 14%
40. Incidence 15%
41. Infections 10%
42. Infliximab 11%
43. Interleukin-6 10%
44. Japan 57%
45. Joints 21%
46. Keratinocytes 12%
47. Knee 14%
48. Laminoplasty 14%
49. Laparoscopy 21%
50. Liver 21%
51. Liver Transplantation 24%
52. Living Donors 19%
53. Lung 10%
54. Lymph Node Excision 17%
55. Lymph Nodes 30%
56. Magnetic Resonance Imaging 11%
57. Methotrexate 40%
58. Multicenter Studies 11%
59. Mutation 10%
60. Neoplasm Metastasis 41%
61. Neoplasms 49%
62. Ossification of Posterior Longitudinal Ligament 15%
63. Osteoclasts 10%
64. Pancreatic Neoplasms 16%
65. Pancreaticoduodenectomy 10%
66. peficitinib 10%
67. Pemphigus 80%
68. Phenotype 10%
69. Placebos 17%
70. Pneumonia 10%
71. Postoperative Complications 15%
72. Prospective Studies 11%
73. Recurrence 28%
74. Retrospective Studies 14%
75. Rheumatoid Arthritis 100%
76. Rheumatology 10%
77. Safety 38%
78. Scoliosis 10%
79. Sentinel Lymph Node 29%
80. Serum 22%
81. Skin 23%
82. Spinal Cord 15%
83. Spinal Cord Diseases 13%
84. Spinal Cord Injuries 12%
85. Spine 21%
86. Squamous Cell Carcinoma 10%
87. Stem Cells 10%
88. Stomach 17%
89. Stomach Neoplasms 54%
90. Surgical Wound Infection 11%
91. Survival 28%
92. Systematic Reviews 11%
93. Systemic Lupus Erythematosus 18%
94. T-Lymphocytes 12%
95. Therapeutics 37%
96. Thorax 19%
97. tocilizumab 25%
98. Tomography 10%
99. Transplantation 10%
100. Transplants 18%